<DOC>
	<DOCNO>NCT01068964</DOCNO>
	<brief_summary>This study evaluate safety efficacy daily administer 0.03 % Bimatoprost/0.5 % Timolol Ophthalmic Solution compare daily administer 0.03 % Bimatoprost Ophthalmic Solution daily administer 0.5 % Timolol Ophthalmic Solution concurrently patient open-angle glaucoma ocular hypertension</brief_summary>
	<brief_title>Safety Efficacy Bimatoprost Timolol Ophthalmic Solution Patients With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis openangle glaucoma ocular hypertension one eye Eye pressure lower topical medication work Visual acuity least 0.2 eye Uncontrolled systemic disease Any active eye disease glaucoma ocular hypertension Significant visual field loss evidence progressive visual field loss within last year Anticipated wear contact lens study Required chronic use ocular medication study Eye surgery laser treatment within 12 week prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>